BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37959874)

  • 21. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study.
    El-Husseiny WM; El-Sayed MA; Abdel-Aziz NI; El-Azab AS; Ahmed ER; Abdel-Aziz AA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):507-518. PubMed ID: 29455554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
    Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrazinecarbonyl-thiazol-2-acetamides with pronounced apoptotic behavior: synthesis, in vitro/in vivo anti-proliferative activity and molecular modeling simulations.
    Elsayed RW; Bayoumi SM; El-Subbagh HI; El-Sayed SM
    Bioorg Med Chem Lett; 2023 May; 87():129285. PubMed ID: 37054758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation.
    Amin NH; El-Saadi MT; Abdel-Fattah MM; Mohammed AA; Said EG
    Bioorg Chem; 2023 Jun; 135():106496. PubMed ID: 36989735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
    Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
    Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of novel pyrimido[4,5-b]quinoline derivatives as dual EGFR/HER2 inhibitors as anticancer agents.
    Ibrahim NSM; Kadry HH; Zaher AF; Mohamed KO
    Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300513. PubMed ID: 38148301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring new quinazolin-4(3H)-one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation.
    Ibrahim BT; Allam HA; El-Dydamony NM; Fouad MA; Mohammed ER
    Drug Dev Res; 2024 Apr; 85(2):e22163. PubMed ID: 38419305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
    Raghunath Khedkar N; Sindkhedkar M; Joseph A
    Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Some 1,3,5-trisubstituted pyrazoline derivatives targeting breast cancer: Design, synthesis, cytotoxic activity, EGFR inhibition and molecular docking.
    George RF; Kandeel M; El-Ansary DY; El Kerdawy AM
    Bioorg Chem; 2020 Jun; 99():103780. PubMed ID: 32224337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, anticancer evaluation, and molecular docking studies of thiazolyl-pyrazoline derivatives.
    Hosseini Nasab N; Azimian F; Shim RS; Eom YS; Shah FH; Kim SJ
    Bioorg Med Chem Lett; 2023 Jan; 80():129105. PubMed ID: 36513215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
    Sobh EA; Khalil NA; Faggal SI; Hassan MSA
    Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
    Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7 Cancer Cells.
    Fakhry MM; Mahmoud K; Nafie MS; Noor AO; Hareeri RH; Salama I; Kishk SM
    Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
    El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
    Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
    Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
    Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
    Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.